Performance status and end-of-life outcomes in patients with metastatic castration resistant prostate cancer treated with androgen receptor targeted therapy
George Mellgard(Memorial Sloan Kettering Cancer Center), Vaibhav G. Patel(Arvinas (United States)), Zakaria Chakrani(Icahn School of Medicine at Mount Sinai), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), Mann Patel(Rutgers, The State University of New Jersey), Nicole Taylor(Icahn School of Medicine at Mount Sinai), Bobby Chi-Hung Liaw(Icahn School of Medicine at Mount Sinai), Nathaniel Saffran(Icahn School of Medicine at Mount Sinai), William Oh(Eunice Kennedy Shriver National Institute of Child Health and Human Development), Che‐Kai Tsao(Mount Sinai Hospital), Stephen McCroskery(Icahn School of Medicine at Mount Sinai)
Cited by 1
Related Papers
Whole-Body Hypothermia for Neonates with Hypoxic–Ischemic Encephalopathy
|New England Journal of Medicine|2005|2.8k
Late-Onset Sepsis in Very Low Birth Weight Neonates: The Experience of the NICHD Neonatal Research Network
|PEDIATRICS|2002|2.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k